Graphic Source: Alkermes plc

Introduction: What is Alkermes plc?

Alkermes plc (ALKS) is a global biopharmaceutical company focused on developing and commercializing products related to schizophrenia, Bipolar I Disorder, Opioid/Alcohol Dependence, and recently Oncology. They are focused on unmet medical needs in major therapeutic areas and retain a diversified portfolio of approved revenue-producing therapeutics and a promising pipeline.

Since its founding in 1987, Alkermes has since grown to over 2,235 employees with revenues of $1.17B and a market cap of $2.68B. Alkermes is headquartered in Ireland with mix-purpose facilities (R&D and manufacturing) also in the USA.

Products: Alkermes has three marketed products, two licensed products, and a few other technology leases that all bring in sustainable revenue of varying levels. Their first product was ARISTADA (aripiprazole lauroxil), a 6w-2m dosing extended-release intramuscular injectable approved in the U.S. for the treatment of schizophrenia. ARISTADA rolled out an add-on, ARISTADA INITIO, which